Regulation of equine infectious anemia virus expression

Journal of Biomedical Science

Volumn 5, Issue 1, 1998, Pages 11-23

  Maury, Wendy ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Cytokine; Equine infectious anemia virus; Gene expression; Lentivirus; Nucleotide variation; Retrovirus; Rev; Splicing; Tat; Transcription factor; Viral pathogenesis

Indexed keywords

EQUINE INFECTIOUS ANEMIA VIRUS; GENE CONTROL; GENE EXPRESSION REGULATION; HORSE; HORSE DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS GENE;

EQUIDAE; EQUINE INFECTIOUS ANEMIA VIRUS; EQUUS CABALLUS; HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRUS; RNA VIRUSES; UNGULATA; UNIDENTIFIED RETROVIRUS;

EID: 0031923166     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/BF02253351     Document Type: Review

References (130)

1. Alexandersen S, Carpenter S. Characterization of variable regions in the envelope and S3 open reading frame of equine infectious anemia virus. J Virol 65:4255-4262;1991.
2. Alonso A, Derse D, Peterlin BM. Human chromosome 12 is required for optimal interactions between Tat and TAR of human immunodeficiency virus type 1 in rodent cells. J Virol 66:4617-4621;1992.
3. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69-73:1985.
4. Ball JM, Payne SL, Issel CJ, Montelaro RC EIAV genomic organization: Further characterization by sequencing of purified glycoproteins and cDNA Virology 165:601-605:1988.
5. Bayer P, Kraft M, Ejchart A, Westendorp M, Frank R, Rosch P Structural studies of HIV-1 Tat protein. J Mol Biol 247:529-535;1995.
6. Beisel CE, Edwards JF, Dunn LL, Rice NR. Analysis of multiple mRNAs from pathogenic equine infectious anemia virus (EIAV) in an acutely infected horse reveals a novel protein, Ttm, derived from the carboxy terminus of the EIAV transmembrane protein. J Virol 67:832-842;1993.
7. Belsham M, Shoemaker AE, Baccam P, Harris ME, Hope TJ, Schommer S, Smith TA, Cornette J, Carpenter S. Biological characterization of Rev variation in equine infectious anemia virus, submitted 1997.
8. Benton CV, Brown BL, Harsham JS, Gilden RV. In vitro host range of equine infectious anemia virus. Intervirology 16:225-232;1981.
9. Berkhout B, Silverman RH, Jeang KT. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59: 273-282;1989.
10. Bogerd HP, Fridell RA, Madore S, Cullen BR. Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. Cell 82:485-494;1995.
11. Calnan BJ, Biancalana S, Hudson D, Frankel AD. Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual features of RNA-protein recognition. Genes Dev 5:201-210;1991.
12. Calnan BJ, Tidor B, Biancalana S, Hudson D, Frankel AD. Arginine-mediated RNA recognition: The arginine fork. Science 252:1167-1171;1991.
13. Carpenter S, Alexandersen S. Pathogenesis of equine infectious anemia virus infection. Semin Virol 3:157-166;1992.
14. Carpenter S, Alexandersen S, Long MJ, Perryman S, Chesebro B. Identification of a hyper-variable region in the long terminal repeat of equine infectious anemia virus. J Virol 65: 1605-1610;1991.
15. Carpenter S, Chesebro B. Change in host cell tropism associated with in vitro replication of equine infectious anemia virus. J Virol 63: 2492-2496;1989.
16. Carpenter S, Evans LH, Sevoian M, Chesebro B. Role of the host immune response in selection of equine infectious anemia virus variants. J Virol 61:3783-3789;1987.
17. Carroll R, Derse D. Translation of equine infectious anemia virus bicistronic tat-rev mRNA requires leaky ribosome scanning of the tat CTG initiation codon. J. Virol 67:1433-1440;1993.
18. Carroll R, Martarano L, Derse D. Identification of lentivirus Tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras. J Virol 65:3460-3467;1991.
19. Carroll R, Peterlin BM, Derse D. Inhibition of human immunodeficiency virus type 1 Tat activity by coexpression of heterologous transactivators. J Virol 66:2000-2007;1992.
20. Carvalho M, Derse D. Mutational analysis of the equine infectious anemia virus Tat-responsive element. J Virol 65:3468-3474;1991.
21. Carvalho M, Derse D. Physical and functional characterization of transcriptional control elements in the equine infectious anemia virus promoter. J Virol 67:2064-2074;1993.
22. Carvalho M, Derse D. The PU.1/Spi-1 protooncogene is a transcriptional regulator of a lentivirus promoter. J Virol 67:3885-3890;1993.
23. Carvalho M, Kirkland M, Derse D. Protein interactions with DNA elements in variant equine infectious anemia virus enhancers and their impact on transcriptional activity. J Virol 67:6586-6595;1993.
24. Cheevers WP, McGuire TC. Equine infectious anemia: Immunopathogenesis and persistence. Rev Infect Dis 7:83-88;1985.
25. Chesebro B, Nishio J, Perryman S, Cann A, O'Brien W, Chen IS, Wehrly K. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol 65:5782-5789;1991.
26. Chun R, Jeang KT. Requirements for RNA polymerase II carboxy-terminal domain for activated transcription of human retroviruses, human T-cell lymphotropic virus I and HIV-1. J Biol Chem 271:27888-27894;1996.
27. Costa LRR, de Miranda Santos IKF, Issel CJ, Montelaro RC. Tumor necrosis factor-alpha production and disease severity after immunization with enriched major core protein (p26) and/or infection with equine infectious anemia virus. Vet Immunol Immunopathol 57:33-47; 1997.
28. Derse D, Carroll R, Carvalho M. Transcriptional regulation of equine infectious anemia virus. Semin Virol 4:61-68;1993.
29. Derse D, Carvalho M, Carroll R, Peterlin BM. A minimal lentivirus Tat. J Virol 65:7012-7015;1991.
30. Derse D, Dorn P, DaSilva L, Martarano L. Structure and expression of the equine infectious anemia virus transcriptional trans-activator (tat). Dev Biol Stand 72:39-48:1990.
31. Derse D, Dorn PL, Levy L, Stephens RM, Rice NR, Casey JW. Characterization of equine infectious anemia virus long terminal repeat. J Virol 61:743-747;1987.
32. Dorn P, DaSilva L, Martarano L, Derse D. Equine infectious anemia virus Tat: Insights into the structure, function, and evolution of lentivirus trans-activator proteins. J Virol 64: 1616-1624;1990.
33. Dorn PL, Derse D. Cis- and trans-acting regulation of gene expression of equine infectious anemia virus. J Virol 62:3522-3526;1988.
34. Folks TM, Justement J, Kinter A, Schnittman S, Orenstein J, Poli G, Fauci AS. Characterization of promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate. J Immunol 140:1117-1122; 1988.
35. Fridell RA, Partin KM, Carpenter S, Cullen BR. Identification of the activation domain of equine infectious anemia virus Rev. J Virol 67: 7317-7323;1993.
36. Garcia-Martinez LF, Mavankal G, Neveu JM, Lane WS, Ivanov D, Gaynor RB. Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription. EMBO J 16:2836-2850;1997.
37. Gatignol A, Kumar A, Rabson A, Jeang KT. Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNA. Proc Natl Acad Sci USA 86:7828-7832;1989.
38. Gaynor RB. Regulation of human immunodeficiency virus type-1 gene expression by the trans-activator protein Tat. Curr Top Microbiol Immunol 193:51-78;1995.
39. Golemis E, Li Y, Fredrickson TN, Hartley YW, Hopkins N. Distinct segments within the enhancer region collaborate to specify the type of leukemia induced by nondefective Friend and Moloney viruses. J Virol 63:328-337;1989.
40. Gontarek RR, Derse D. Interactions among SR proteins, and exonic splicing enhancer, and a lentivirus Rev protein regulate alternative splicing. Mol Cell Biol 16:2325-2331;1996.
41. Graves BJ, Rabson AB. Retrovirus gene expression: Transcription and RNA processing. In: Coffin J, Hughes S, Varmus H, eds. Retro-viruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998, in press.
42. Gutekunst DE, Becvar CS. Responses in horses infected with equine infectious anemia virus adapted to tissue culture. Am J Vet Res 40: 974-977;1979.
43. Hammond SA, Cook SJ, Lichtenstein DL, Issel CJ, Montelaro RC. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 71:3840-3852;1997.
44. Hoffman D, White S. NMR analysis of the trans-activation response (TAR) RNA element of equine infectious anemia virus. Nucleic Acids Res 23:4058-4065;1995.
45. Hope T, Pomerantz RJ. The human immuno-deficiency virus type 1 Rev protein: A pivotal protein in the viral life cycle. Curr Top Microbiol Immunol 193:91-106;1995.
46. Hope TJ, Bond BL, McDonald D, Klein NP, Parslow TG. Effector domains of human immunodeficiency virus type 1 Rev and human T-cell leukemia virus type 1 Rex are functionally interchangeable and share an essential peptide motif. J Viral 65:6001-6007;1991.
47. Huang L-H, Wang R, Gama-Sosa S, Shenoy S, Ehrlich M. A protein from human nuclei binds preferentially to 5-methylcytosine-rich DNA. Nature 308:293-295;1984.
48. Issel CJ, Adams WV, Meek L, Ochoa R. Transmission of equine infectious anemia virus from horses without clinical signs of disease. J Am Vet Med Assoc 180:272-275;1982.
49. Issel CJ, Coggins L. Equine infectious anemia: Current knowledge. J Am Vet Med Assoc 174: 727-733;1979.
50. Issel CJ, Horohov DW, Lea DF, Adams WV, Hagius SD, McManus JM, Allison AC, Montelaro RC. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 66:3398-3408;1992.
51. Kim CH, Casey JW. In vivo replicative status and envelope heterogeneity of equine infectious anemia virus in an inapparent carrier. J Virol 68:2777-2780;1994.
52. Klevjer-Anderson P, Cheevers WP, Crawford TB. Characterization of the infection of equine fibroblasts by equine infectious anemia virus. Arch Virol 60:279-289;1979.
53. Kono Y. Viremia and immunological responses in horses infected with equine infectious anemia virus. Natl Inst Anim Health Q 9: 1-9;1969.
54. Kono Y, Hirasawa K, Fukunaga Y, Taniguchi T. Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs. Natl Inst Anim Health Q 16:667-674;1975.
55. Kono Y, Kobayashi K, Fukunaga Y. Antigenic drift of equine infectious anemia virus in chronically infected horses. Arch Ges Virus-forsch 41:1-10;1973.
56. Kono Y, Yokomizo Y. Attempts to cultivate the equine infectious anemia virus in various types of cells. Natl Inst Anim Health Q 8:182-186:1968.
57. Kono Y, Yoshino T, Fukunaga Y. Propagation and titration of equine infectious anemia virus in horse leucocyte culture. Natl Inst Anim Health Q 7:8-20;1967.
58. Langemeier JL, Cook SJ, Cook RF, Rushlow KE, Montelaro RC, Issel CJ. Detection of equine infectious anemia viral RNA in plasma samples from recently infected and long-term inapparent carrier animals by PCR. J Din Microbiol 34:1481-1487;1996.
59. Leonard J, Parrott C, Buckler-White AJ, Turner W, Ross E, Martin M, Rabson AB. The NF-kB binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol 63:4919-4924:1989.
60. Li Y, Golemis E, Hartley JW, Hopkins N. Disease specificity of nondefective Friend and Moloney in urine leukemia viruses is controlled by a small number of nucleotides. J Virol 61:693-700;1989.
61. Lichtenstein DL, Issel CJ, Montelaro RC. Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J Virol 70:3346-3354;1996.
62. Lichtenstein DL, Rushlow KE, Cook RF, Raabe ML, Swardson CJ, Kociba GJ, Issel CJ, Montelaro RC. Replication in vitro and in vivo of an equine infectious anemia virus mutant deficient in dUTPase activity. J Virol 69:2881-2888;1995.
63. Madore SJ, Cullen BR. Genetic analysis of the cofactor requirement for human immunodeficiency virus type I Tat function. J Virol 67: 3703-3711;1993.
64. Malim MH, Bohnlein S, Fenrick R, Le S-Y, Maizel JV, Cullen BR. Functional comparison of the Rev trans-activators encoded by different primate immunodeficiency virus species. Proc Natl Acad Sci USA 86:8222-8226;1989.
65. Malim MH, Hauber J, Le S, Maizel JV, Cullen BR. The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254-257;1989.
66. Malquist WA, Burnett D, Becvar CS. Production of equine infectious anemia antigen in a persistently infected cell line. Arch Ges Virus-forsch 42:361-370;1973.
67. Mancuso RA, Hope TJ, Zhu L, Derse D, Phillips T, Parslow TO. Posttranslational effector domains in the Rev proteins of feline immunodeficiency virus and equine infectious anemia virus. J Virol 68:1998-2001;1994.
68. Marciniak RA, Garcia-Blanco MA, Sharp PA. Identification and characterization of a HeLa nuclear protein that specifically binds to the trans-activation-response (TAR) element of human immunodeficiency virus. Proc Natl Acad Sci USA 87:3624-3628;1990.
69. Martarano L, Stephens R, Rice N, Derse D. Equine infectious anemia virus trans-regulatory protein Rev controls viral mRNA stability, accumulation, and alternative splicing. J Virol 68:3102-3111;1994.
70. Maury W. Monocyte maturation controls expression of equine infectious anemia virus. J Virol 68:6270-6279;1994.
71. Maury W, Carpenter S, Graves K, Chesebro B. Cellular and viral specificity of equine infectious anemia virus Tat trans-activation. Virology 200:632-642;1994.
72. Maury WJ, Oaks JL, Bradley S. In vitro propagation of equine infectious anemia virus in equine endothelial cells, submitted 1998.
73. Maury WJ, Ferryman S, Seid B, Oaks JL, McGuire T, Crawford T, Carpenter S. Localized sequence heterogeneity of in vivo equine infectious anemia virus LTRs. J Virol 71: 4929-4937;1996.
74. McGuire T, Tumas D, Byrne KM, Hines MT, Leib SR, Brassfield AL, O'Rourke KJ, Perryman LE. Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/Pr proteins. J Virol 68: 1459-1467;1994.
75. McGuire TC, Crawford TB, Henson JB. Immunofluorescent localization of equine infectious anemia virus in tissue. Am J Pathol 62: 283-294;1971.
76. Michael NL, Mo T, Merzouki A, O'Shaughnessy M, Oster C, Burke DS, Redfield RR, Birx DL, Cassol SA. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol 69:1868-1877; 1995.
77. Monuchi M, Moriuchi H, Turner W, Fauci AS. Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol 159:4322-4329;1997.
78. Muesing MA, Smith DH, Capon DJ. Regulation of mRNA accumulation by a human immunodeficiency virus trans-activator protein. Cell 48:691-701;1987.
79. Mujeeb A, Parslow TG, Yuan Y-C, James TL. Aqueous solution structure of a hybrid lentiviral Tat peptide and a model of its interaction with HTV-1 TAR RNA. J Biomol Struct Dyn 13:649-660;1996.
80. Myers G, Korber B, Foley B, Jeang K-T, Mellors JW, Wain-Hobson S. Human Retrovirus and AIDS 1996: A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM, Los Alamos Natl Lab, 1996.
81. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 326: 711-713;1987.
82. Nekhai S, Shukla RR, Kumar A. A human primary T-lymphocyte-derived human immunodeficiency virus type 1 Tat-associated kinase phosphorylates the C-terminal domain of RNA polymcrase II and induces CAK activity. J Virol 71:7436-7441;1997.
83. Noiman S, Yaniv A, Tsach T, Miki T, Tronick SR, Gazit A. The Tat protein of equine infectious anemia virus is encoded by at least three types of transcripts. Virology 184:521-530; 1991.
84. O'Brien WA, Koyanagi Y, Namazie A, Zbai J-Q, Diagne A, Idler K, Zack JA, Chen ISY. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature 348:69-73; 1990.
85. O'Rourke KI, Perryman LE, McGuire TC. Antiviral, anti-glycoprotein and neutralizing antibodies in foals with equine infectious anemia virus. J Gen Virol 69:667-674;1988.
86. Oaks JL, McGuire TC, Ulibarri C, Crawford TB. Subclinical equine infectious anemia virus infection: Viral load and host cells, submitted 1997.
87. Oaks JL, Ulibarri C, Crawford JB. Endothelial cell infection by equine infectious anemia virus, submitted 1998.
88. Orrego A, Issel JC, Montelaro RC, Adams WV Jr. Virulence and in vitro growth of a cell-adapted strain of equine infectious anemia virus after serial passage in ponies. Am J Vet Res 43.1556-1560;1982.
89. Parrott C, Seidner T, Duh E, Leonard J, Theodore TS, Buckler-White A, Martin M, Rabson AB. Variable role of the long terminal repeat Sp1-binding sites in human immuno-deficiency virus replication in T lymphocytes. J Virol 65:1414-1419;1991.
90. Payne S, Fang F, Liu C, Dhruva B, Rwambo P, Issel JC, Montelaro RC. Antigenic variation and lentivirus persistence: Variations in envelope gene sequences during EIAV infection resemble changes reported for sequential isolates of HIV. Virology 161:321-331;1987.
91. Payne S, Salinovich O, Nauman SM, Issel CJ, Montelaro RC. Course and extent of variation of equine infectious anemia virus during parallel persistent infections. J Virol 61: 1266-1270;1987.
92. Payne SL, Qi X-M, Shao H, Dwyer A, Fuller FJ. Disease induction by virus derived from molecular clones of equine infectious anemia virus. J Virol 72, in press.
93. Payne SL, Rausch J, Rushlow K, Montelaro RC, Issel C, Flaherty M, Perry S, Sellon D, Fuller F. Characterization of infectious molecular clones of equine infectious anemia virus. J Gen Virol 75:425-429;1994.
94. Perry ST, Flaherty MT, Kelley MJ, Clabough DL, Tronick SR, Coggins L, Whetter L, Lengel CR, Fuller F. The surface envelope protein gene region of equine infectious anemia virus is not an important determinant of tropism in vitro. J Virol 66:4085-4097;1992.
95. Perryman LE, O'Rourke KI, Mason PH, McGuire TC. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J Virol 62:3073-3076;1988.
96. Powell DM, Amaral MC, Wu JY, Maniatis T, Greene WC. HIV Rev-dependent binding of SF2/ASF to the Rev response element: Possible role in Rev-mediated inhibition of HIV RNA splicing. Proc Natl Acad Sci USA 94: 973-978;1997.
97. Rice NR, Henderson LE, Sowder RC, Copeland TD, Oroszlan S, Edwards FJ. Synthesis and processing of the transmembrane envelope protein of equine infectious anemia virus. J Virol 64:3770-3778;1990.
98. Rice NR, Lequarre AS, Casey JW, Lahn S, Stephens RM, Edwards FJ. Viral DNA in horses infected with equine infectious anemia virus. J Virol 63:5194-5200;1989.
99. Rosen CA, Terwilliger E, Dayton A, Sodroski JG, Haseltine WA. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc Natl Acad Sci USA 85:2071-2075;1988.
100. Rosin-Arbesfeld R, Mashiah P, Willbold D, Rosch P, Tronick S, Yaniv A, Gazit A. Biological activity and intracellular location of the Tat protein of equine infectious anemia virus. Gene 150:307-311:1994.
101. Rosin-Arbesfeld R, Rivlin M, Noiman S, Mashiah P, Yaniv A, Miki T, Tronick SR, Gazit A. Structural and functional characterization of rev-like transcripts of equine infectious anemia virus. J Virol 67:5640-5646;1993.
102. Ross EK, Buckler-White AJ, Rabson AB, Englund G, Martin MA. Contribution of NF-kB and Sp1 binding motifs to the replicative capacity of human immunodeficiency virus type 1: Distinct patterns of viral growth are determined by T-cell types. J Virol 65:4350-4358;1991.
103. Saksela K, Stevens C, Rubinstein P, Baltimore D. Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc Natl Acad Sci USA 91:1104-1108; 1994.
104. Schiltz RL, Shih DS, Rasty S, Montelaro RC, Rushlow KE. Equine infectious anemia virus gene expression: Characterization of the RNA splicing pattern and the protein products encoded by open reading frames S1 and S2. J Virol 66:3455-3465;1992.
105. Sellon DC. Equine infectious anemia. Vet Clin North Am Equine Pract 9:321-336; 1993.
106. Sellon DC, Perry ST, Coggins L, Fuller FJ. Wild-type equine infectious anemia virus replicates in vivo predominantly in tissue macrophages, not in peripheral blood monocytes. J Virol 66:5906-5913;1992.
107. Sellon DC, Walker KM, Russell KE, Perry ST, Fuller FJ. Phorbol ester stimulation of equine macrophage cultures alters expression of equine infectious anemia virus. Vet Microbiol 52:209-221;1996.
108. Sheline CT, Milocco LH, Jones KA. Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin. Genes Dev 5:2508-2520; 1991.
109. Sherman L, Yaniv A, Lichtman-Pleban H, Tronick SR, Gazit A. Analysis of regulatory elements of the equine infectious anemia virus and caprine arthritis-encephalitis virus long terminal repeats. J Virol 63:4925-4931; 1989.
110. Short MK, Okenquist SA, Lenz J. Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats. J Virol 61: 1967-1972;1987.
111. Smith TA, Davis E, Carpenter S. Endotoxin treatment of EIAV-infected horse macrophage culture decreases production of infectious virus, submitted 1997.
112. Steagall WK, Robek MD, Perry ST, Fuller FJ, Payne SL. Incorporation of uracil into viral DNA correlates with reduced replication of EIAV in macrophages. Virology 210:302-313;1995.
113. Stephens RM, Derse D, Rice NR. Cloning and characterization of cDNAs encoding equine infectious anemia virus Tat and putative Rev proteins. J Virol 64:3716-3725; 1990.
114. Sticht S, Willbold D, Bayer P, Ejchart A, Hermann F, Rosin-Arbesfeld R, Gazit R, Yaniv A, Frank R, Rosch P. Equine infectious anemia virus Tat is a predominantly helical protein. Eur J Biochem 218:973-976; 1993.
115. Tan W, Schalling M, Zhao C, Luukkonen M, Nilsson M, Fenyo EM, Pavlakis GN, Schwartz S. Inhibitory activity of the equine infectious anemia virus major 5′ splice site in the absence of Rev. J Virol 70:3645-3658; 1996.
116. Tornquist SJ, Crawford TB. Suppression of megakaryocyte colony growth by plasma from foals infected with equine infectious anemia virus. Blood 90:2357-2363;1997.
117. Tumas DB, Mines MT, Ferryman LE, Davis WC, McGuire TC. Corticosteroid immuno-suppression and monoclonal antibody-mediated CD5+ T lymphocyte depletion in normal and equine infectious anaemia virus-carrier horses. J Gen Virol 75:959-968;1994.
118. Wang SZ-S, Rushlow KE, Issel CJ, Cook RF, Cook SL, Raabe ML, Chong Y-H, Costa L, Montelaro RC. Enhancement of EIAV replication and disease by immunization with baculovirus-expressed recombinant envelope surface glycoprotein. Virology 199:247-251; 1994.
119. Westervelt P, Gendelman HE, Ratner L. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci USA 88:3097-3101;1991.
120. 119a Whetter L, Archambault D, Perry S, Gazit A, Coggins L, Yaniv A, Clabough D, Dahlberg J, Fuller F, Tronick S. Equine infectious anemia virus derived from a molecular clone persistently infects horses. J Virol 64:5750-5756; 1990.
121. Willbold D, Kruger U, Frank R, Rosin-Arbesfeld R, Gazit A, Yaniv A, Rosch P. Sequence-specific resonance assignments of the H-NMR spectra of a synthetic, biologically active EIAV Tat protein. Biochemistry 32: 8439-8445;1993.
122. Willbold D, Rosin-Arbesfeld R, Sticht H, Frank R, Rosch P. Structure of the equine infectious anemia virus Tat protein. Science 264:1584-1587:1994.
123. Wright CM, Felber BK, Paskalis H, Pavlakis GN. Expression and characterization of the trans-activator of HTLV-III/LAV virus. Science 234:988-992;1986.
124. Wu F, Garcia J, Sigman D, Gaynor R. Tat regulates binding of the human immunodeficiency virus trans-activating region RNA loop-binding protein TRP-185. Genes Dev 5: 2128-2140;1991.
125. Yang X, Herrmann CH, Rice AP. The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function. J Virol 70:4576-4584; 1996.
126. Zhang D, Hetherington O, Chen H, Tenen DG. The macrophage transcription factor PU.1 directs tissue-specific expression of the macrophage colony-stimulating factor receptor. Mol Cell Biol 14:373-381;1994.
127. Zhang DE, Hetherington CJ, Meyers S, Rhoades KL, Larson CJ, Chen HM, Hiebert SW, Tenen DG. CCAAT enhancer-binding protein (C/EBP) and AML1 (CBF alpha2) synergistically activate the macrophage colony-stimulating factor receptor promoter. Mol Cell Biol; 16:1231-1240;1996.
128. Zhang DE, Hohaus S, Voso MT, Chen HM, Smith LT, Hetherington CJ, Tenen DG. Function of PU.1 (Spi-1), C/EBP, and AML1 in early myelopoiesis: Regulation of multiple myeloid CSF receptor promoters. Curr Top Microbiol Immunol 211:243-252;1996.
129. Zhang X-Y, Inamdar NM, Supakar PC, Wu K, Ehrlich KC, Ehrlich M. Three MDBP sites in the enhancer-promoter region of human cytomegalovirus. Virology 182:865-869; 1991.
130. Zhang X-Y, Jabrane-Ferrat N, Asiedu CK, Samac S, Peterlin BM. Ehrlich M. The major histocompatibility complex class II promoter-binding protein RFX (NF-X) is a methylated DNA-binding protein. Mol Cell Biol 13: 6810-6818;1993.